While the tough funding environment has forced many biotechs to lay off staff or pare back their pipelines, Jounce has at least found a way to make some easy money in the process. The biotech has sold ...

There’s significant change on the way at Jounce Therapeutics. The embattled clinical-stage company announced Wednesday afternoon that it is laying off more than half of its workforce as part of a ...

Shares of Jounce Therapeutics JNCE were up 21.2% on Mar 27 after management announced that the company entered into an agreement with Concentra Biosciences (“Concentra”) wherein the former will ...

It ain’t over ‘til it’s over and for Redx Pharma, it’s over. Redx and Jounce Therapeutics announced Monday morning that the two companies agreed to terminate their proposed business combination ...

The Board of Directors of Jounce Therapeutics Inc (NASDAQ: JNCE) confirmed that Concentra Biosciences LLC made an unsolicited and non-binding proposal to acquire 100% of the equity of Jounce. Tang ...

CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and ...

-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature- - JTX-8064’s mechanism of action ...

Jounce Therapeutics (NASDAQ:JNCE) is merging with U.K.-based Redx Pharma in an all stock deal after which the combined company will be known as Redx and listed on Nasdaq under the ticker REDX. The ...

FILE PHOTO: The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California (Reuters) - Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS ...

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring ...

Will the biotech IPO market be better in 2017? Cambridge, Massachusetts-based Jounce Therapeutics hopes so. A low-key filing on Dec. 30 with the Securities and Exchange Commission (SEC) shows the ...

Jounce Therapeutics has upsized its IPO and beaten the anticipated price range, bumping up its final haul to $104 million. The Celgene-partnered immuno-oncology player will use the cash to advance a ...